Condition: Metastatic Castration Resistant Prostate Cancer · mCRPC · mCRPC (Metastatic Castration-resistant Prostate Cancer) · Sponsor: Flare Therapeutics Inc.
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects. Participants will take FX-111 every day by mouth and will have regular physical and laboratory examinations to check health and tumor status.
This description comes directly from the study's public registry record.
Janine Koucheki, Associate Director, Clinical Operations · 857-706-4400 · clinops@flaretx.com
Carolyn McCrone, Sr Clinical Trial Associate · 857-706-4400 · clinops@flaretx.com
Always discuss trial participation with your own doctor first.
| START Los Angeles | Los Angeles, California, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START New Jersey | East Brunswick, New Jersey, United States | Recruiting |
| START Carolinas | Myrtle Beach, South Carolina, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Not Yet Recruiting |
| START Dallas-Fort Worth | Fort Worth, Texas, United States | Recruiting |
| NEXT Houston | Houston, Texas, United States | Not Yet Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Not Yet Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07719361